Petros Pharmaceuticals, Inc. (PTPI)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$3.5M
Stockholders' Equity
$700,894
Cash & Equivalents
$3.5M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Petros Pharmaceuticals, Inc. reported net income of -$955,625 and total assets of $3.5M. Every figure below is taken directly from Petros Pharmaceuticals, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2020–FY2024 · as reported

$9.6M-$5.5M-$20.6M
FY2020FY2021FY2022FY2023FY2024
Revenue$5.1MNet income-$14.3M
FY2020 revenue
$9.6M
FY2024 revenue
$5.1M

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—$1.9M
FY2024$5.1M-$14.3M
FY2023$5.8M-$8.2M
FY2022$6.0M-$20.0M
FY2021$7.8M-$9.0M
FY2020$9.6M-$20.6M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KSep 30, 2026on EDGAR ↗
10-QAug 13, 2026on EDGAR ↗
8-KJun 18, 2026on EDGAR ↗
8-KJun 5, 2026on EDGAR ↗
10-QMay 13, 2026on EDGAR ↗
10-KApr 15, 2026on EDGAR ↗
NT 10-KMar 31, 2026on EDGAR ↗
8-KJan 2, 2026on EDGAR ↗
10-QNov 13, 2025on EDGAR ↗
8-KNov 7, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$3.5Msource ↗
Stockholders’ Equity$700,894source ↗
Cash & Equivalents$3.5Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$955,625source ↗
Operating Income-$988,501source ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense—source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.30source ↗
EPS (basic)$-0.30source ↗
Shares Outstanding42.4Msource ↗
Cash from Operations-$863,855source ↗
Cash from Financing—source ↗
Cash from Investing—source ↗

Insider activity

Form 4 open-market activity, last 180 days

No open-market Form 4 transactions filed in the last 180 days.

Restatement history

Point-in-time

3 of 163 annual fact-keys were materially restated between filings: what Petros Pharmaceuticals, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches PTPI’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/PTPI

MCP tool: get_sec_fundamentals ticker=PTPI

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/PTPI/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=PTPI as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/PTPI/history

MCP tool: get_fundamentals_history ticker=PTPI

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/PTPI

MCP tool: get_financial_health ticker=PTPI

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.